Overview
SRPT market data
Price History
SRPT price chart
Valuation & Profitability
- P/E (TTM)
- 24.89 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$7.13 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.22 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $14.68 – $25.32 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · source Twelve Data /statistics · market cap $1.6K · P/B 1.98 · P/S 0.74.
Company News
8-K filing — Sarepta Therapeutics, Inc. (SRPT)SEC EDGAR · Jul 27, 2026, 1:08 PM
Sarepta Therapeutics Appoints Michael Severino CEO, Effective July 28, Succeeding Doug IngramBenzinga · Jul 27, 2026, 12:37 PM
Piper Sandler Maintains Neutral on Sarepta Therapeutics, Lowers Price Target to $20Benzinga · Jul 9, 2026, 3:40 PM
Wolfe Research Upgrades Sarepta Therapeutics to Outperform, Announces $27 Price TargetBenzinga · Jul 9, 2026, 12:15 PM
Sarepta Moves Closer To FDA Approval For Duchenne Muscular Dystrophy DrugsBenzinga · Jun 30, 2026, 4:50 PM
Sarepta Therapeutics Says FDA Accept sNDAs For AMONDYS 45 And VYONDYS 53 For Treatment Of Duchenne Muscular Dystrophy; PDUFA Target Action Data February 28, 2027Benzinga · Jun 30, 2026, 12:40 PM
Small Caps Near Record Highs, Robinhood Rallies 12%: Stock Market TodayBenzinga · Jun 17, 2026, 5:40 PM
My Top 3 Biotech Stocks for May 2026The Motley Fool · May 20, 2026, 4:15 PM
Protein Synthesis Research Market to Reach $42.8 Billion by 2031, Driven by Surging CGT InvestmentGlobenewswire Inc · May 18, 2026, 7:15 PM